Harvard Management Company’s Praxis Precision Medicines PRAX Stock Holding History

Harvard Management Company’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-46,174	Closed	-$797K	–	29
2023 Q2	$797K	Sell	46,174 -5,727	-11%	-$87.7K	0.08%	28
2023 Q1	$630K	Hold	51,901	–	–	0.07%	43
2022 Q4	$1.85M	Hold	51,901	–	–	0.23%	35
2022 Q3	$1.77M	Hold	51,901	–	–	0.22%	37
2022 Q2	$1.91M	Hold	51,901	–	–	0.22%	35
2022 Q1	$7.95M	Hold	51,901	–	–	0.8%	17
2021 Q4	$15.3M	Hold	51,901	–	–	1.44%	12
2021 Q3	$14.4M	Hold	51,901	–	–	0.84%	17
2021 Q2	$14.2M	Hold	51,901	–	–	0.82%	20
2021 Q1	$25.5M	Sell	51,901 -940	-2%	-$668K	1.42%	14
2020 Q4	$43.6M	Buy	+52,841	New	+$30.8M	2.37%	8

Other funds holding PRAX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Harvard Management Company's PRAX Position: Q3 2023 in Review

Harvard Management Company sold out of Praxis Precision Medicines (PRAX) in Q3 2023, closing a stake of 46,174 shares — an estimated $797K sold.

Harvard Management Company first reported a position in PRAX in Q4 2020 and held it in 11 quarters. The position peaked at $43.6M in Q4 2020. 74 funds tracked by Wall St. Rank hold PRAX as of Q3 2023.

Harvard Management Company reported no remaining Praxis Precision Medicines position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 46,174 Praxis Precision Medicines shares in Q3 2023, an estimated $797K.
Harvard Management Company first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 11 quarters.
Harvard Management Company's Praxis Precision Medicines position peaked at $43.6M in Q4 2020.
74 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.